Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy

Thumann, Peter; Lüftl, Matthias; Moc, Isabelle; Bagot, M.; Bensussan, Armand; Jenne, Lars

doi:10.1111/j.1365-2133.2003.05674.x

Cited by 14 publications

(11 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are studies suggesting that dermal dendritic cells are active against tumor cells and present tumor-specific antigens to other reactive T lymphocytes with the progression of the malignancy [13]. Therefore, dendritic- cell-based vaccination aiming at the induction of antitumoral immunity has been used in multiple clinical trials [14, 15]. All except 2 reported cases seem to exhibit a benign clinical behavior (table 1).…”

Section: Discussionmentioning

confidence: 99%

Ichthyosiform Mycosis fungoides: Report of a Case Associated with IgA Nephropathy

et al. 2005

View full text Add to dashboard Cite

We report a case of ichthyosiform mycosis fungoides (MF) associated with IgA nephropathy. Histological examination showed a dense atypical lymphocytic infiltrate admixed with epithelioid cells and giant cells in the dermis associated with the features of epidermotropism and folliculotropism. Reported cases of ichthyosiform MF are reviewed and histopathological characters of ichthyosiform MF are summarized. We suggest a histiocyte/dendritic-cell-rich infiltrate, or granulomatous features of infiltrate may be another characteristic of ichthyosiform MF. This case was associated with IgA nephropathy, which is uncommon. Such a presentation has never been reported in the literature.

show abstract

Section: Discussionmentioning

confidence: 99%

Ichthyosiform Mycosis fungoides: Report of a Case Associated with IgA Nephropathy

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Adenoviral-mediated gene therapies that increase expression of IFN-γ have also been used successfully in CTCL ( 51 – 53 ). CTCL cells can inhibit T-cell proliferation and suppress dendritic cell (DC) maturation by secretion of Th2 cytokines ( 54 ). Skin and nasal colonization with Staphylococcus aureus is common in patients with MF/SS; in particular, a Th2-dominant microenvironment may underlie this susceptibility to infection ( 55 ).…”

Section: Th2-dominant Microenvironmentmentioning

confidence: 99%

“…Dendritic cells are antigen-presenting cells with a unique capacity to induce primary immune responses ( 90 ). By secreting Th2 cytokines, CTCL cells can suppress the maturation of DCs ( 54 ). Notably, IL-10 downregulates DC functions and may promote tolerance by skin DCs, rather than immune defense ( 91 ).…”

Section: Dendritic Cellsmentioning

confidence: 99%

New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma

Fujii

2018

Front. Oncol.

View full text Add to dashboard Cite

Primary cutaneous lymphomas comprise a group of lymphatic malignancies that occur primarily in the skin. They represent the second most common form of extranodal non-Hodgkin’s lymphoma and are characterized by heterogeneous clinical, histological, immunological, and molecular features. The most common type is mycosis fungoides and its leukemic variant, Sézary syndrome. Both diseases are considered T-helper cell type 2 (Th2) diseases. Not only the tumor cells but also the tumor microenvironment can promote Th2 differentiation, which is beneficial for the tumor cells because a Th1 environment enhances antitumor immune responses. This Th2-dominant milieu also underlies the infectious susceptibility of the patients. Many components, such as tumor-associated macrophages, cancer-associated fibroblasts, and dendritic cells, as well as humoral factors, such as chemokines and cytokines, establish the tumor microenvironment and can modify tumor cell migration and proliferation. Multiagent chemotherapy often induces immunosuppression, resulting in an increased risk of serious infection and poor tolerance. Therefore, overtreatment should be avoided for these types of lymphomas. Interferons have been shown to increase the time to next treatment to a greater degree than has chemotherapy. The pathogenesis and prognosis of cutaneous T-cell lymphoma (CTCL) differ markedly among the subtypes. In some aggressive subtypes of CTCLs, such as primary cutaneous gamma/delta T-cell lymphoma and primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, hematopoietic stem cell transplantation should be considered, whereas overtreatment should be avoided with other, favorable subtypes. Therefore, a solid understanding of the pathogenesis and immunological background of cutaneous lymphoma is required to better treat patients who are inflicted with this disease. This review summarizes the current knowledge in the field to attempt to achieve this objective.

show abstract

“…It is known that CTCL cells can hamper proliferation of reactive T cells and suppress maturation of dendritic cells (DCs) by secretion of a T H 2-dominated cytokine profile. 2 IL-10 especially down-regulates DC function and may induce tolerance of skin DCs rather than immune defense. 3,4 The main characteristic of CTCL in the early stages is the trapping of the malignant T-cell clone in the skin, which can be achieved by a specific set of chemokines.…”

mentioning

confidence: 99%

Up-Regulation of the Chemokine CCL18 by Macrophages Is a Potential Immunomodulatory Pathway in Cutaneous T-Cell Lymphoma

Günther

Zimmermann

Berndt

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

Mycosis fungoides (MF) is the most frequent form of cutaneous T-cell lymphoma (CTCL), which can deteriorate from patch stage to dermal-based tumors and systemic involvement in years. The interaction of chemokines in the skin with CTCL cells might have implications for the pathogenesis of the disease. In this study, we show by PCR analysis and immunofluorescence staining that the chemokine CCL18 is present in skin biopsy specimens of patients with MF and its precursor form parapsoriasis en plaque but not in healthy tissue. In addition, the serum levels of CCL18 were increased threefold in MF patients compared with those in healthy controls. In skin, CCL18 was specifically expressed by CD163 ؉ CD209 ؉ macrophages at the invasive margin of the tumor and not expressed by mature CD208 ؉ dendritic cells in the center of the tumor. The chemokine CCL17 was, by contrast, ubiquitously expressed. Furthermore, CCL18 promoted the chemotaxis but not the proliferation of CTCL cells. CCL18 inhibited proliferation of tumor cells and abolished the CXCL12-induced growth of a CTCL cell line. These data link the increased expression of CCL18 with CTCL and suggest an immunomodulatory effect of the chemokine in the pathogenesis

show abstract

Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy

Abstract: Together, these data argue in favour for a DC-based immunotherapy for CTCL patients and provide an experimental protocol for preparing CTCL cell-loaded DCs.

Cited by 14 publications

References 67 publications

Ichthyosiform Mycosis fungoides: Report of a Case Associated with IgA Nephropathy

Ichthyosiform Mycosis fungoides: Report of a Case Associated with IgA Nephropathy

New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma

Up-Regulation of the Chemokine CCL18 by Macrophages Is a Potential Immunomodulatory Pathway in Cutaneous T-Cell Lymphoma

Contact Info

Product

Resources

About